ASTRAZENECA PHARMA INDIA Financial Statement Analysis
|
||
|
The Revenues of ASTRAZENECA PHARMA INDIA have decreased by -0.98% YoY .
The Earnings Per Share (EPS) of ASTRAZENECA PHARMA INDIA has increased by 61.20 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
ASTRAZENECA PHARMA INDIA Last 5 Annual Financial Results
[BOM: 506820|NSE : ASTRAZEN]
| Standalone | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹806 Cr | ₹814 Cr | ₹832 Cr | ₹728 Cr | ₹571 Cr |
| Expenses | ₹719 Cr | ₹678 Cr | ₹711 Cr | ₹657 Cr | ₹525 Cr |
| Operating Profit (Excl OI) | ₹86 Cr | ₹135 Cr | ₹121 Cr | ₹71 Cr | ₹46 Cr |
| Other Income | ₹15 Cr | ₹13 Cr | ₹13 Cr | ₹16 Cr | ₹12 Cr |
| Interest | ₹0.95 Cr | ₹1.09 Cr | ₹1.14 Cr | ₹0.00 Cr | ₹0.00 Cr |
| Depreciation | ₹17 Cr | ₹20 Cr | ₹19 Cr | ₹15 Cr | ₹15 Cr |
| Profit Before Tax | ₹83 Cr | ₹127 Cr | ₹114 Cr | ₹73 Cr | ₹44 Cr |
| Profit After Tax | ₹62 Cr | ₹93 Cr | ₹72 Cr | ₹54 Cr | ₹26 Cr |
| Consolidated Net Profit | ₹62 Cr | ₹93 Cr | ₹72 Cr | ₹54 Cr | ₹26 Cr |
| Earnings Per Share (Rs) | ₹39.72 | ₹24.64 | ₹37.32 | ₹28.88 | ₹21.78 |
| PAT Margin (%) | 9.85 | 7.61 | 11.42 | 8.65 | 7.44 |
| ROE(%) | 18.13 | 12.78 | 22.83 | 21.83 | 20.03 |
| ROCE(%) | 24.49 | 17.36 | 31.24 | 34.61 | 26.53 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 13,334.6 Cr |
| Revenue (TTM) | : | ₹ 1,197.0 Cr |
| Net Profit(TTM) | : | ₹ 139.3 Cr |
| EPS (TTM) | : | ₹ 55.7 |
| P/E (TTM) | : | 95.7 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ASTRAZENECA PHARMA INDIA | 3.1% | 6% | 66.8% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.1% | -2.8% | 50.3% |
| CIPLA | 4.5% | -3.1% | 52.8% |
| DR REDDYS LABORATORIES | 4.6% | 1.4% | 22.2% |
| ZYDUS LIFESCIENCES | 3.1% | -4.1% | 80.4% |
| DIVIS LABORATORIES | 4.7% | 10.8% | 18.1% |
| MANKIND PHARMA | 2.7% | 12.4% | NA |
| TORRENT PHARMACEUTICALS | 6.1% | 5.3% | 66.2% |
| LUPIN | 3.1% | -1.1% | 127.4% |
ASTRAZENECA PHARMA INDIA Revenues
[BOM: 506820|NSE : ASTRAZEN]
| Y-o-Y | -0.98 % |
| 5 Yr CAGR | 8.99 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹806 Cr | -0.98 | |
| Mar2022 | ₹814 Cr | -2.19 | |
| Mar2021 | ₹832 Cr | 14.21 | |
| Mar2020 | ₹728 Cr | 27.55 | |
| Mar2019 | ₹571 Cr | - | |
ASTRAZENECA PHARMA INDIA Operating Profit
[BOM: 506820|NSE : ASTRAZEN]
| Y-o-Y | -36.38 % |
| 5 Yr CAGR | 16.81 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹86 Cr | -36.38 | |
| Mar2022 | ₹135 Cr | 12.24 | |
| Mar2021 | ₹121 Cr | 69.28 | |
| Mar2020 | ₹71 Cr | 54.03 | |
| Mar2019 | ₹46 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -35.74 % |
| 5 Yr CAGR | 7.17 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 10.7% | -35.74 | |
| Mar2022 | 16.65% | 14.75 | |
| Mar2021 | 14.51% | 48.21 | |
| Mar2020 | 9.79% | 20.72 | |
| Mar2019 | 8.11% | - | |
ASTRAZENECA PHARMA INDIA Profit After Tax
[BOM: 506820|NSE : ASTRAZEN]
| Y-o-Y | -33.98 % |
| 5 Yr CAGR | 24.17 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹62 Cr | -33.98 | |
| Mar2022 | ₹93 Cr | 29.21 | |
| Mar2021 | ₹72 Cr | 32.62 | |
| Mar2020 | ₹54 Cr | 110.15 | |
| Mar2019 | ₹26 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 29.43 % |
| 5 Yr CAGR | 7.27 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 9.85 % | 29.43 | |
| Mar2022 | 7.61 % | -33.36 | |
| Mar2021 | 11.42 % | 32.02 | |
| Mar2020 | 8.65 % | 16.26 | |
| Mar2019 | 7.44 % | - | |
ASTRAZENECA PHARMA INDIA Earnings Per Share (EPS)
[BOM: 506820|NSE : ASTRAZEN]
| Y-o-Y | 61.20 % |
| 5 Yr CAGR | 16.21 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹40 | 61.20 | |
| Mar2022 | ₹25 | -33.98 | |
| Mar2021 | ₹37 | 29.22 | |
| Mar2020 | ₹29 | 32.60 | |
| Mar2019 | ₹22 | - | |
ASTRAZENECA PHARMA INDIA Return on Capital Employed (ROCE)
[BOM: 506820|NSE : ASTRAZEN]
| Y-o-Y | 41.07 % |
| 5 Yr CAGR | -1.98 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 24.49% | 41.07 | |
| Mar2022 | 17.36% | -44.43 | |
| Mar2021 | 31.24% | -9.74 | |
| Mar2020 | 34.61% | 30.46 | |
| Mar2019 | 26.53% | - | |
ASTRAZENECA PHARMA INDIA Share Price vs Sensex
| Current Share Price | : | ₹5,333.9 |
| Current MarketCap | : | ₹ 13,334.6 Cr |
| Updated EOD on | : | Apr 25,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ASTRAZENECA PHARMA INDIA | 3.1% |
6% |
66.8% |
| SENSEX | 1.3% |
2.6% |
24% |
ASTRAZENECA PHARMA INDIA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE SMALL CAP | 3.2% | 12.8% | 65.7% |
| S&P BSE 250 SMALLCAP | 2.5% | 12.8% | 64.9% |
| S&P BSE MIDSMALLCAP | 2.4% | 10.7% | 64.9% |
| S&P BSE 400 MIDSMALLCAP | 1.9% | 9.9% | 59.4% |
| S&P BSE ALLCAP | 1.6% | 6% | 40.6% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY SMALLCAP250 | 2.8% | 13.8% | 71.1% |
| NIFTY MID SMALL400 | 2.1% | 10.7% | 62.3% |
| NIFTY500 MULTICAP 50:25:25 | 1.8% | 7.7% | 48.1% |
| NIFTY 500 | 1.5% | 5.7% | 39.5% |
You may also like the below Video Courses
FAQ about ASTRAZENECA PHARMA INDIA Financials
How the annual revenues of ASTRAZENECA PHARMA INDIA have changed ?
The Revenues of ASTRAZENECA PHARMA INDIA have decreased by -0.98% YoY .
How the Earnings per Share (EPS) of ASTRAZENECA PHARMA INDIA have changed?
The Earnings Per Share (EPS) of ASTRAZENECA PHARMA INDIA has increased by 61.20 % YoY .
Check out Intrinsic Value of Peers of ASTRAZENECA PHARMA INDIA
Compare Stock Analytics of Peers of ASTRAZENECA PHARMA INDIA
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
